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ABSTRACT 
A novel modified biomaterial of periwinkle shell powder, MBPSP was developed from Tympanotonus fuscata. It was assessed as a 
bulking agent in the formulation of pyrimethamine and pyridoxine hydrochloride tablets adopting dicalcium phosphate dihydrate 
(DCP) as a standard. A 100 g of the ground periwinkle shell was broken down in 166.0 ml of 2 M hydrochloric acid, clarified and 
treated with 5 M sodium hydroxide. The thick white precipitate obtained was washed severally and to it, ortho-phosphoric acid was 
dropped in bits until a thick, dehydrated bulk was attained which was dried at 60 o C and classified with 250 μm sieve. The product 
was coded MBPSP. Two batches of granules containing pyrimethamine (25 mg) and pyridoxine hydrochloride (50 mg) were 
generated by the wet granulation employing MBPSP alongside DCP. The granules were lubricated with magnesium stearate and talc 
and compacted into tablets at 7.55kN using a 10.50 mm diameter die and flat-faced punch fixed in a hydraulic hand press. The tablet 
produced were evaluated using the British Pharmacopoeia specifications. The weight variation for the pyrimethamine or pyridoxine 
hydrochloride tablets containing MBPSP or DCP were 0.06, 0.1, 0.097 and 0.143 % respectively. The total drug content for the 
individual lots of tablets for either pyrimethamine or pyridoxine hydrochloride was within 85.00-115.00 % of their label claim. 
Higher mechanical strength were noted for the batch of tablets manufactured with DCP and containing pyrimethamine and 
pyridoxine hydrochloride than MBPSP. Though the entire batches of tablets for the two drugs manufactured with either MBPSP or 
DCP disintegrated in less than 5.00 min with no significant difference in their individual disintegrating time (p>0.05), pyridoxine 
hydrochloride tablets prepared with DCP disintegrated in lesser time when compared to MBPSP (p<0.05). Only the pyrimethamine 
tablets prepared with MBPSP attained 75.00 % drug release in 45.00 min in line with the United States Pharmacopoeia (USP) 
criteria. Therefore, MBPSP could be another very useful bulking agent in the formulation of pyrimethamine immediate-release 
tablets by the wet granulation technique.   
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INTRODUCTION  
Administration of drug products through the mouth is 
often the ideal path for the use of drugs since is a cheap 
way of drug treatment, simply managed, users easily 
adapt to the direction for the use of the medicinal 
product, changes in any drug formulation is easy to 
adjust to, etc. In the past years, several drug products 
administered through the mouth have been designed
1
. 
Tablets are single compact dosage formulae designed to 
be administered orally. They are prepared from 
combination of pulverized solid materials encompassing 
the therapeutically viable substance or the active 
ingredient (API). It also includes several ingredients 
which assist in the compression of intact tablet. Tablets 
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are usually produced through the process of wet 
granulation (WG), dry granulation (DG) or direct 
compression (DC). Any of these methods have its gains 
and inconveniences
2
. The adoption of any of these 
processes may actually depend on the nature of the 
pharmaceutical excipient available for use among other 
factors around the API.  
It has been noted that inactive ingredients are blended in 
addition to the API in order to enhance the tableting 
properties as well as its bioavailability. The 
pharmaceutical excipients may be categorized 
considering their application in the production of tablet. 
They comprise diluents, binders, glidants, lubricants, 
disintegrants, plasticizers, etc.
3
. They influence the 
stability, bioavailability and the process by which the 
tablets are prepared. Diluents are usually utilized to 
enhance the required size of a tablet for effective 
management. This is the reason they are referred to as 
bulking agents or fillers
4
. An ideal diluents like other 
ingredients added in addition to the API, are expected to 
be chemically and physiologically inactive and should 
not conflict with the bioavailability of the API. Such 
excipients are also expected to be easily sourced and 
affordable and should be easily manipulated to a tablet. 
Instances of diluents comprise lactose, dry starch, 
sucrose, mannitol, calcium sulphate, dicalcium 
phosphate, etc.
5
. Most pharmaceutical inactive 
ingredients originated from natural materials. They may 
be generated either chemically or by other means and 
they have been utilized in the pharmaceutical sector as 
tablet binders, disintegrants, bulking agents, etc.
6, 7
.  
Tympanotonus fuscata var Radula (L) is also noted as 
the periwinkle. It has a protection of shell and is 
described as a Mollusca which the foremost marine 
animal possessing an outer frame is termed shell
8
.  
In this studies, the milled shell of Tympanotonus fuscata 
was improved and applied to size-up tablets in the 
production of pyrimethamine and pyridoxine 
hydrochloride tablets by the wet granulation procedure. 
Similar tablets containing dicalcium phosphate 
dihydrate (DCP) as diluent was formulated. The 
production and early assessment of the physical and 
some chemical nature of the biological material of the 
shell of T. fuscata has been recorded
9
. The physico-
chemical characteristics of the adjusted micronized 
material derived from the Tympanotonus fuscata shell 
(MBPSP) in line with possible utilization in the 
pharmaceutical sector has as well been cited in the 
literature
10
. Ugoeze and Udeala stated the use of a bio-
ash resultant from the periwinkle shell as a carbon 
dioxide (CO2) donor in the making of an effervescent 
low dose aspirin tablet
11
. 
MATERIALS AND METHODS 
Materials 
The following materials were used and include: 
hydrochloric acid (HCl), sodium hydroxide (M&B, 
England), gelatin (Fisher, USA), dicalcium phosphate 
dihydrate (DCP) (Rousselot, Belgium), corn starch, 
magnesium stearate, talc, ethanol (BDH, England). 
Pyrimethamine and pyridoxine hydrochloride were 
donated by Juhel Nigeria Ltd.  
Methods 
Preparation of modified biomaterial of 
Tympanotonus fuscata shell powder  
The procedure documented by Ugoeze and Chukwu was 
adopted
10
. A 100 g of the micronized shell of 
Tympanotonus fuscata was broken-down in 166.0 ml of 
2 M hydrochloric acid, removing extraneous materials 
by filtration. The acidic filtrate was neutralized with 5 
M sodium hydroxide. The white precipitate obtained 
was washed severally.  Ortho-phosphoric acid was 
dropped in bits to the profuse aqueous suspension of the 
mass to achieve a dense, dehydrated mass which was 
dried to constant weight at 60 
o
 C in hot air oven 
(Uniscope, England). The dried mass was classified with 
a 250 μm stainless steel sieve (Retch, Germany). The 
powder was stored in an amber coloured powder bottle 
and was referred to in this work as the modified 
biomaterial of periwinkle shell powder (MBPSP). 
Formulation of tablet 
Table 1: Formula for producing pyrimethamine tablet 
using MBPSP or DCP. Each tablet contains 25 mg of 
pyrimethamine and weighs 200 mg 
Ingredient Percentage per tablet (% w/w) 
Pyrimethamine 12.50 
Gelatin 2.00 
Corn starch 10.00 
Magnesium stearate 1.00 
Talc 0.50 
MBPSP or DCP 74.00 
 
Table 2: Formula for the production of pyridoxine 
hydrochloride tablets using MBPSP or DCP. Each tablet 
contains 50 mg of pyridoxine hydrochloride and weighs 
300 mg 
Ingredient Percentage per tablet    
(% w/w) 
Pyridoxine hydrochloride 16.66 
Gelatin 2.00 
Corn starch 10.00 
Magnesium stearate 1.00 
Talc 0.50 
MBPSP or DCP 69.84 
  
Granulation  
Using the formula shown in Tables 1 and 2, granules of 
pyrimethamine (25 mg) or pyridoxine hydrochloride (50 
mg) respectively were produced by the wet granulation 
technique. In each formulation, the API was blended 
with corn starch and the MBPSP or DCP to attain 
consistency. A paste of gelatin was made in a little 
warm water and incorporated into the respective powder 
blends to wet-mass them. More water was sprinkled and 
it was kneaded further and granulated through sieve 10 
(1.7 mm). It was dried in a hot air oven at 60 
o 
C.  The 
batches of the dried mass were screened with sieve 16 
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(1.00 mm) and the granules obtained were stored in 
airtight amber coloured glass containers.  
Compression of tablets 
Each batch of the granules containing pyrimethamine or 
pyridoxine hydrochloride and prepared with MBPSP or 
DCP was mixed with magnesium stearate and talc 
respectively and compressed for 30 s at a compression 
pressure of 7.35 kN making use of a 10.5 mm diameter 
die and flat-faced punches on a hydraulic hand press 
(Model C, Carver Laboratory Press, Menomonee Falls, 
WI. USA). All the compressed tablets were left in a 
desiccator for 24 h before their properties were 
evaluated. 
Evaluation of tablets  
The respective batches of tablets containing 
pyrimethamine or pyridoxine hydrochloride and 
prepared with MBPSP or DCP were evaluated as 
outlined in the procedures below. A triplicate readings 
was obtained each time and their mean was computed.   
Uniformity of tablet weight  
The weight of twenty tablets from each batch containing 
pyrimethamine or pyridoxine hydrochloride and 
produced with either MBPSP or DCP were determined 
individually on an electronic balance (Mettler, 
Germany)
12
.   
Uniformity of tablet thickness 
Using a micrometer screw gauge (VIS, Poland), the 
thickness of each tablet in the respective batches used 
for uniformity of weight was measured. 
Tablet hardness  
The hardness of ten tablets from the batches containing 
pyrimethamine or pyridoxine hydrochloride and 
produced with MBPSP or DCP was evaluated
12
 making 
use of a digital hardness tester (DBK Instruments, 
England. 
Tablet friability 
Using ten tablets from each batch which were dusted, 
weighed and positioned in a tablet friabilator (Veego 
Tablet Friability Test Apparatus, India) regulated at 25 
revolution per minute (rpm) for 4 min, the friability of 
each batch was determined.  
Tablet disintegration time 
The time for the complete break-down of six tablets 
from the respective batches containing pyrimethamine 
or pyridoxine hydrochloride and designed using MBPSP 
or DCP was estimated in disintegration apparatus 
(Veego Disintegration Apparatus, India). The instrument 
consisted of a rigid basket-rack assembly backup of six 
cylindrical glass tubes.  A 1L of 0.1N hydrochloric acid 
contained in a glass beaker served as a medium which 
was kept at 37 ± 1
o 
C. Tablet break-down was recorded 
when no deposit of undissolved tablet persisted on the 
screen of the test apparatus
12
. 
Tablet total drug content 
From each batch of pyrimethamine and pyridoxine 
hydrochloride tablets respectively, ten wholesome 
tablets were crushed and the mass of powders 
corresponding to the mean weight of the individual lots 
was evaluated spectrophotometrically for its intact 
content of the API.   
Tablet tensile strength 
The tensile strength for the respective batches of tablets 
was calculated from the equation below: 
              
Dissolution rate studies   
The dissolution rate studies for pyrimethamine and 
pyridoxine hydrochloride tablets respectively was 
considered in a dissolution apparatus 2, the paddle 
method (Erweka DT 80, Germany), individually 
operated at the speed of 50  revolutions per minute 
(rpm) for both pyrimethamine and pyridoxine 
hydrochloride in 900 ml of 0.1 N hydrochloric acid kept 
at 37 ± 1
o 
C
12
. In each case, a 5.0 ml of sample was 
taken out of the medium at the time intervals between 
5.0- 45.0 min, changing same with 5.0 ml of plain 0.1N 
hydrochloric acid solution each time. The absorption of 
the dissolved solutions of the APIs was read in a 
Spectrophotometer 160-A (Japan) at 253 and 290 nm for 
pyrimethamine and pyridoxine hydrochloride 
respectively.  
Statistical analysis 
All statistical analysis of data involving the Independent 
T-Test was carried out using the IBM SPSS Statistics 20 
software. 
RESULTS AND DISCUSSIONS 
Physical properties of tablets 
The properties of the pyrimethamine or pyridoxine 
hydrochloride tablets prepared with MBPSP or DCP are 
shown in Tables 3 and 4 respectively.  
Appearance of tablets 
The tablets of both drugs with MBPSP or DCP were 
glossy. There was no discolouration.  
Tablet weight uniformity and thickness 
The weight variation for the pyrimethamine or 
pyridoxine hydrochloride tablets containing MBPSP or 
DCP was 0.06, 0.1, 0.097 and 0.143 % respectively. The 
British Pharmacopoeia (12) specified up to 7.5% for 
weight variation for tablets weighing 130-324 mg. The 
results of the weight variation were low and may be due 
evenness in the flowability of granules during the 
tableting. Statistical analysis showed that there was no 
major variances in the weights of tablets in the 
individual lots of the pyrimethamine and pyridoxine 
hydrochloride produced with MBPSP or DCP (p>0.05). 
A comparable result was similarly obtained for 
respective tablet thickness for pyrimethamine and 
pyridoxine hydrochloride for the two bulking agents 
examined.
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Table 3: Properties of pyrimethamine tablet prepared with MBPSP or DCP 
Tablet parameter  MBPSP DCP P value 
Uniformity of weight (mg) 199.89±0.37 200.20±0.56 P>0.05 
Thickness (mm) 1.80±0.12 1.54±0.13 P<0.05 
Drug Content (%) 25.56±0.5 25.62±0.65 P<0.05 
Disintegration time (min) 2.20±0.26 2.00±0.26 P>0.05 
Hardness (N) 77.19±0.47 81.18±0.22 P<0.05 
Friability (%) 0.90±0.01 0.84±0.01 P<0.05 
Tensile strength (mN/m
2
)  3396.75±0.24 3576.80±0.56 P<0.05 
HFR
* 
86.25±0.35 93.45±0.48 P<0.05 
*Hardness Friability Ratio. 
Table 4: Properties of pyridoxine hydrochloride tablet prepared with MBPSP or DCP 
Tablet parameter  MBPSP DCP P value 
Uniformity of weight (mg) 300.29±0.61 300.43±1.40 P>0.05 
Thickness (mm) 1.80±0.01 1.51±0.03 P<0.05 
Drug Content (%) 51.76±0.87 50.92±1.05 P>0.05 
Disintegration time (min) 3.95±0.07  2.37±0.32 P<0.05 
Hardness (N) 168.01±0.22 101.03±0.16 P<0.05 
Friability (%) 0.79±0.01  0.95±0.63 P<0.05 
Tensile strength (mN/m
2
)  5656.34±0.43 3983.26±0.45 P<0.05 
HFR
* 
216.98±0.19 106.18±0.18 P<0.05 
*Hardness Friability Ratio 
Total drug content 
The results of the total drug content for pyrimethamine 
and pyridoxine hydrochloride containing MBPSP or 
DCP were 102.24, 102.48, 103.52 and 101.84 %. None 
was lower than 85 % or above 115%. The British 
Pharmacopoeia
12
 specified that a preparation complies 
with the test for total drug content if each individual 
content is between 85.00 % and 115.00 % of the average 
content. There was no significant variation in the values 
for MBPSP and DCP (p>0.05).  
Tablet mechanical strength 
A tablet hardness of 4.00 kg (≈39.00 N) is commonly 
the minimum for acceptable tablets
13
. Tablets 
administered by mouth usually possess a hardness of 
4.00 -10.00 kg (≈39.00 – 98.00 N). Tablet hardness 
mainly increase in value with consistent storing of 
tablets and is affected by the shape, chemical properties, 
binding agent and the compacting pressure used to 
prepare the tablet
14, 15
.   
The friability test is strictly interconnected to tablet 
hardness and is intended to assess the capability of the 
tablet to stand abrasions in container during 
transportation. A friability of less than 1.00 % is 
assessed as acceptable particularly for tablets 
manufactured by wet granulation. However, tablets 
made by direct compaction could result to friability 
above unity
16
. 
The tensile strength is an additional factor utilized to 
evaluate the strength of tablets in withstanding wear and 
tear. It is a degree of the bonding power of a tablet
17
. 
The grouping of the tablet hardness and friability, a 
word chosen as the hardness-friability ratio (HFR) 
which is one more estimation of the mechanical strength 
of pharmaceutical tablets
14, 15, 18
. The hardness offers an 
estimation of tablet mechanical strength while the 
friability provides the degree of the tablet softness. 
Investigations have revealed that the greater the HFR 
values, the stronger the tablet
14, 15
.  In terms of tablet 
mechanical strength, it was generally recorded that 
higher values of mechanical strength were noted for 
tablets containing DCP in both pyrimethamine and 
pyridoxine hydrochloride than MBPSP. This trend was 
consistent from the results obtained for friabilty, tensile 
strength and hardness-friability-ratio (HFR) (p<0.05).    
Disintegration time 
For a good number of plain tablets, the British 
Pharmacopoeia call for tablets crumbling within 15 min 
when in contact with water even though the value may 
be different for other types of uncoated tablets. For 
tablets that are coated, up to 2 hours may be needed for 
complete crumbling of a tablet when in contact with a 
fluid
12, 19-21
.  
The entire batches of tablets containing either 
pyrimethamine or pyridoxine hydrochloride, 
manufactured with either MBPSP or DCP disintegrated 
in less than 5 min.  However, for pyrimethamine tablets, 
there was no significant difference in the disintegrating 
time between tablets containing either MBPSP or DCP 
(p>0.05). Meanwhile, for pyridoxine tablets, those 
prepared with DCP had lower disintegration timing 
when compared to MBPSP (p<0.05).  
Drug dissolution 
The dissolution rate profiles for pyrimethamine and 
pyridoxine hydrochloride tablets made with either 
MBPSP or DCP are displayed in Figures 1 and 2 
respectively. The United States Pharmacopoeia (USP) 
22 
specified that not less than 75.00 % of the stated 
quantity of pyrimethamine ought to be dissolved in 
45.00 min. For pyridoxine hydrochloride   tablet, the 
USP also stated that not less than 75.00 % of the noted 
amount should be released in solution in 45.00 min.   
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Figure 1: Dissolution rate profile for pyrimethamine 
tablets prepared with MBPSP or DCP in 0.1 N HCl at 
37 ± 1
o 
C 
 
Figure 2: Dissolution rate profile for the pyridoxine 
hydrochloride tablets formulated with MBPSP or DCP 
in 0.1 N HCl at 37 ± 1
o 
C 
Considering Figure 1, maximal amount (88.00 %) of 
pyrimethamine was released at 25.00 min from MBPSP. 
Not up to 75.00 % of the same drug could be dissolved 
after 45.00 min. Figure 2 depicts that neither MBPSP 
nor DCP could release up to 75.00% of pyridoxine 
hydrochloride from the tablets formulated with either, 
though, the rate of release of pyridoxine hydrochloride 
was higher in MBPSP.  These results suggest that the 
formulation of pyrimethamine employing MBPSP 
complied with the USP requirements for its drug release. 
Neither MBPSP nor DCP was suitable for pyridoxine 
hydrochloride tablets.   
CONCLUSION 
A novel inert material applicable as a tablet bulking 
agent, MBPSP has been made available from the shell 
of the T. fuscata. Having been utilized as a bulking 
agent in a pilot manufacture of pyrimethamine and 
pyridoxine hydrochloride tablets adopting the wet 
granulation technique in comparison with a commercial 
product, DCP. It was noted that MBPSP will be 
preferable in the formulation of pyrimethamine tablet 
than DCP. It was also recorded that neither MBPSP nor 
DCP was suitable in the formulation of pyridoxine 
hydrochloride tablets since up to the USP specified 
amount could not be released from their tablets after the 
maximum period of dissolution studies.  
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